JBJane E. Burdick

Jane E. Burdick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jane E. Burdick has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of spirodioxolane nsP2 helicase inhibitors with antialphaviral activity

    by Hans J. Oh, John D. Sears, Bose Muthu Ramalingam, Rahman Shah Zaib Saleem, Zachary W. Davis-Gilbert, Mohammed Anwar Hossain, Stella R. Moorman, Durbadal Ohja, Sabian A. Martinez, Jane E. Burdick, et al.

    Spirodioxolanes were identified as a new series of direct-acting nsP2 helicase inhibitors with activity against alphaviruses. Analogs such as 6b maintained activity against viral mutants with resistance to first-generation nsP2 helicase inhibitors.

  • Open Access

    Identification of Spirodioxolane nsP2 Helicase Inhibitors with Antialphaviral Activity

    by Hans Oh, John Sears, Muthu Bose Ramalingam, Rahman Shah Zaib Saleem, Zachary Davis-Gilbert, Mohammed Anwar Hossain, Stella Moorman, Durbadal Ojha, Sabian Martinez, Jane Burdick, et al.

    We describe the design, synthesis, and antialphaviral activity of spirodioxolane inhibitors targeting the alphavirus nsP2 helicase (nsP2hel). The spirodioxolanes are a new series of direct-acting antivirals that retain key molecular features required for inhibition of nsP2hel, including a highly substituted piperidine acetamide with its associated conformational isomerism and thermal mobility. Unlike the related oxaspiropiperidine nsP2hel inhibitors, the spirodioxolanes showed no enantioselectivity in their antiviral activity. The spirodioxolanes demonstrated antialphaviral activity against the Old World alphavirus Chikungunya virus, with some analogs also showing activity against the New World alphavirus Venezuelan equine encephalitis virus. Importantly, certain spirodioxolane analogs, such as 6b, maintained activity against viral mutants that displayed resistance to first-generation oxaspiropiperidine inhibitors, indicating their potential for optimization as a new class of broad-spectrum antialphaviral drugs.

  • Open Access

    N -Alkyl Sulfamates as a New Class of nsP2 Cysteine Protease Inhibitors with Broad Spectrum Antialphaviral Activity

    by Anirban Ghoshal, John D. Sears, Mohammad Anwar Hossain, Edwin G. Tse, Stephanie Howell, Jane E. Burdick, Noah L. Morales, Sabian A. Martinez, Isabella Law, Zachary J. Streblow, et al.

    The emergence of mosquito-borne alphaviruses that cause chronic arthritis or encephalitis underscores the urgent need for broad-spectrum antiviral therapeutics. The viral nsP2 cysteine protease, which is essential for alphavirus replication, is a promising antiviral target. Vinyl sulfone-based inhibitors, such as RA-2034, potently inhibit nsP2 protease but suffer from glutathione reactivity and species-dependent systemic clearance catalyzed by glutathione S -transferase. To address these liabilities, we explored alternative electrophilic warheads and identified reverse amide inhibitors bearing N -alkyl sulfamate warheads with improved biochemical and antiviral profiles. N -methyl sulfamate acetamide 5 emerged as a lead compound with potency against both New and Old World alphaviruses, low GSH reactivity, and high proteome-wide selectivity. Despite its promising antialphaviral activity, 5 exhibited rapid clearance due to hepatic glucuronidation. Structure–activity studies revealed modifications that improve metabolic stability while retaining antiviral activity. These findings introduce sulfamate acetamides as a new class of covalent nsP2 protease inhibitors and advance the discovery of direct acting pan-alphavirus drugs.


  • Open Access

    Identification of Direct-acting nsP2 Helicase Inhibitors with Antialphaviral Activity

    by Muthu Ramalingam Bose, John D. Sears, Kacey M. Talbot, Yuan-Wei Norman Su, Scott Houliston, Mohammed Anwar Hossain, Zachary W. Davis-Gilbert, Chunqing Zhao, Hans J. Oh, Peter J. Brown, et al.

    Alphaviruses are mosquito-borne RNA viruses that pose a significant public health threat, with no FDA-approved antiviral therapeutics available. The non-structural protein 2 helicase (nsP2hel) is an enzyme involved in unwinding dsRNA essential for alphavirus replication. This study reports the discovery and optimization of first-in-class oxaspiropiperidine inhibitors targeting nsP2hel. Structure-activity relationship (SAR) studies identified potent cyclic sulfonamide analogs with nanomolar antiviral activity against chikungunya virus (CHIKV). Biochemical analyses of nsP2hel ATPase and RNA unwindase activities showed these compounds act by a non-competitive mode suggesting that they are allosteric inhibitors. Viral resistance mutations mapped to nsP2hel and a fluorine-labeled analog exhibited direct binding to the protein by 19 F NMR. The lead inhibitor, 2o , demonstrated broad-spectrum antialphaviral activity, reducing titers of CHIKV, Mayaro virus (MAYV), and Venezuelan equine encephalitis virus (VEEV). These findings support nsP2hel as a viable target for development of broad-spectrum direct-acting antialphaviral drugs. Graphical


  • Open Access

    U-CAN-seq: A Universal Competition Assay by Nanopore Sequencing

    by Jennifer Diaz, John Sears, Che-Kang Chang, Jane Burdick, Isabella Law, Wes Sanders, Colton Linnertz, Paul Sylvester, Nathaniel Moorman, Martin T. Ferris, et al.

    RNA viruses quickly evolve subtle genotypic changes that can have major impacts on viral fitness and host range, with potential consequences for human health. It is therefore important to understand the evolutionary fitness of novel viral variants relative to well-studied genotypes of epidemic viruses. Competition assays are an effective and rigorous system with which to assess the relative fitness of viral genotypes. However, it is challenging to quickly and cheaply distinguish and quantify fitness differences between very similar viral genotypes. Here, we describe a protocol for using reverse transcription PCR in combination with commercial nanopore sequencing services to perform competition assays on untagged RNA viruses. Our assay, called the Universal Competition Assay by Nanopore Sequencing (U-CAN-seq), is relatively cheap and highly sensitive. We used a well-studied N24A mutation in the chikungunya virus (CHIKV) nsp3 gene to confirm that we could detect a competitive disadvantage using U-CAN-seq. We also used this approach to show that mutations to the CHIKV 5′ conserved sequence element that disrupt sequence but not structure did not affect the fitness of CHIKV. However, similar mutations to an adjacent CHIKV stem loop (SL3) did cause a fitness disadvantage compared to wild-type CHIKV, suggesting that structure-independent, primary sequence determinants in this loop play an important role in CHIKV biology. Our novel findings illustrate the utility of the U-CAN-seq competition assay.